Longevity & Aging · Metabolic & Cardiometabolic
exogenous insulin therapy for T2D worsens long-term T2D outcomes
In plain terms: Does taking insulin for type 2 diabetes make the disease worse over time?
No — the one large randomized trial (ORIGIN) found insulin cardiovascular-neutral, and long-term follow-up (UKPDS) shows a durable benefit, not harm. Observational 'insulin causes harm' signals are confounded (sicker patients get insulin). Important: this is not a reason to stop or reduce prescribed insulin — for many people, especially with type 1 diabetes, insulin is life-saving, and any change should only be made with your physician.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
>
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Adler 2024 · Lancet | RCT | contradicts | high | 24-yr UKPDS monitoring found enduring/emerging glycemic legacy benefit from early intensive control (including insulin arm), with no waning, arguing against long-term harm from the insulin-containing strategy. |
| Currie 2013 · J Clin Endocrinol Metab | observational | supports | low | Retrospective cohort linked insulin vs other antihyperglycemic therapies to higher mortality and diabetes-related outcomes, raising safety concerns but unable to exclude that sicker patients receive insulin. |
| Holman 2008 · N Engl J Med | RCT | contradicts | high | 10-yr post-trial follow-up of intensive glucose control (sulfonylurea/insulin) showed sustained reduction in microvascular disease and emergent reductions in myocardial infarction and all-cause mortality (legacy effect), opposite to a worsening-progression claim. |
| Abid 2026 · Ann Med Surg | observational | mixed | moderate | Confirms insulin's characteristic adverse effects — hypoglycemia and weight gain — the concrete harms underlying part of Fung's argument, though these are side effects, not proof of accelerated disease progression. |
| Buse 2015 · Rev ACCORD | RCT | mixed | moderate | Intensive glycemic control targeting near-normal HbA1c raised all-cause mortality (trial stopped early), but the signal was not insulin-specific and is attributed to the intensive strategy/hypoglycemia/rapid lowering, not to insulin per se. |
| Abdella 2002 · Kuwait Med J | mechanism | contradicts | low | Reviews the hyperinsulinemia-is-atherogenic hypothesis and concludes high insulin is a marker of insulin resistance, not a proven direct cause of atherosclerosis; benefit of glycemic control outweighs the theoretical hyperinsulinemia concern. |
| Holden 2015 · Diabetes Obes Metab | observational | supports | low | In insulin-monotherapy T2D, higher insulin dose was associated with increased all-cause mortality, MACE and cancer — but observationally, with strong confounding by indication. |
| Currie 2018 · Diabetes Obes Metab | observational | mixed | low | Association between achieved HbA1c and survival differed by regimen's hypoglycemia risk (U-shaped, worse at low HbA1c on insulin/sulfonylurea), implicating hypoglycemia/glucose level rather than insulin causing progression. |
| Lin 2025 · Sci Rep | observational | mixed | moderate | Confirmed U-shaped HbA1c-mortality/MACE relationship; both high and low glucose raise risk, with lowest-risk HbA1c about 6.7-7.2%, indicating danger is dysglycemia/overtreatment, not insulin therapy itself. |
| Hanefeld 2016 · Diabetes Ther | RCT | contradicts | moderate | In the ORIGIN RCT, about 6.7 yr of basal insulin glargine had a NEUTRAL effect on cardiovascular disease vs standard care, with prevention of glycemic worsening, few severe hypoglycemia episodes, and only moderate weight gain. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.